Nelson Sun Sells 62,000 Shares of Aardvark Therapeutics (NASDAQ:AARD) Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) insider Nelson Sun sold 62,000 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the transaction, the insider owned 35,475 shares in the company, valued at $183,760.50. The trade was a 63.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Nelson Sun also recently made the following trade(s):

• On Thursday, September 10th, Nelson Sun sold 14,754 shares of Aardvark Therapeutics stock. The shares were sold at an average price of $5.00, for a total transaction of $73,770.00.

Aardvark Therapeutics Price Performance

Shares of AARD stock traded up $0.12 during midday trading on Friday, reaching $5.13. 276,559 shares of the company traded hands, compared to its average volume of 128,424. The firm’s 50 day simple moving average is $6.29 and its two-hundred day simple moving average is $5.53. Aardvark Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $17.94. The firm has a market cap of $112.24 million, a PE ratio of -1.60 and a beta of 3.74.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21. As a group, research analysts anticipate that Aardvark Therapeutics, Inc. will post -3.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AARD. HC Wainwright reaffirmed a “neutral” rating and set a $6.00 price target on shares of Aardvark Therapeutics in a research note on Monday, July 20th. Morgan Stanley reissued an “underweight” rating and issued a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. Wall Street Zen upgraded shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. B. Riley Financial cut their target price on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, BTIG Research downgraded shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $15.33.

Institutional Trading of Aardvark Therapeutics

A number of large investors have recently made changes to their positions in the stock. SymBiosis Capital Partners LLC acquired a new position in Aardvark Therapeutics in the 4th quarter valued at about $6,255,000. Millennium Management LLC purchased a new position in Aardvark Therapeutics in the 3rd quarter valued at about $4,248,000. BlackRock Inc. acquired a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth about $1,077,000. Geode Capital Management LLC boosted its stake in shares of Aardvark Therapeutics by 53.5% during the 4th quarter. Geode Capital Management LLC now owns 297,865 shares of the company’s stock worth $3,910,000 after purchasing an additional 103,830 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Aardvark Therapeutics by 20.6% during the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock worth $7,386,000 after buying an additional 94,744 shares in the last quarter.

Key Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
• Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
• Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
• Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
• Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.